ClinicalTrials.gg
Active, not recruitingNCT06684847UnityUpdated Apr 16, 2026

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

A Phase 3 interventional study of Efgartigimod PH20 SC and Placebo PH20 SC in Primary Sjogrens Disease, sponsored by argenx. Active, not recruiting at 303 sites in 39 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by argenx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
631
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD). The study consists of a double-blinded placebo-controlled treatment period and an open-label treatment period. The maximum study duration for participants in both study parts is approximately 105 weeks.

02

Conditions studied

  • Primary Sjogrens Disease
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF.
  • Meets the following criteria at screening: fulfilled ACR/EULAR classification criteria 2016 PSjD criteria before screening; clinESSDAI ≥ 6 at screening; Anti-Ro/SS-A positive at central laboratory; Unstimulated residual salivary flow (≥ 0.01 mL/min)

Exclusion criteria

Exclusion Criteria:

  • Secondary (also referred to as associated) Sjögren's disease, defined as overlap with another rheumatic or systemic inflammatory condition (eg, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, or idiopathic inflammatory myopathy
  • Active fibromyalgia which is not adequately controlled in the judgment of the investigator, or participant is receiving fibromyalgia treatment that has not been stable treatment for at least 12 weeks before screening.
  • Any severe systemic pSjD manifestation that is not adequately controlled at screening or baseline that may put the participant at undue risk based on the investigator's opinion.
  • Use of cyclophosphamide ≤ 24 weeks prior to screening
  • Anti-CD20 or anti-CD19 antibody received \< 6 months before screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
631 participants (actual)

Study arms

  • Experimental
    Double-blinded treatment period: Efgartigimod PH20 SC

    Participants receiving efgartigimod PH20 SC during the double-blinded treatment period

    Biological: Efgartigimod PH20 SC

  • Placebo comparator
    Double-blinded treatment period: Placebo PH20 SC

    Participants receiving placebo PH20 SC during the double-blinded treatment period

    Other: Placebo PH20 SC

  • Experimental
    Open-label treatment period

    Participants receiving efgartigimod PH20 SC during the open-label treatment period

    Biological: Efgartigimod PH20 SC

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in clinESSDAI score at week 48

    The ESSDAI was designed to measure systemic disease activity in patients with PSjD and consists of 12 domains. The score varies between 0 (no disease activity) and 123 (max disease activity). The clinESSDAI includes all ESSDAI domains except the biological domain.

    Time frame: Up to 48 weeks

Secondary outcomes

  1. Change from baseline in ESSDAI score at week 48

    The ESSDAI was designed to measure systemic disease activity in patients with PSjD and consists of 12 domains. The score varies between 0 (no disease activity) and 123 (max disease activity).

    Time frame: Up to 48 weeks

  2. Proportion of participants with low disease activity (clinESSDAI < 5) at week 48

    The ESSDAI was designed to measure systemic disease activity in patients with PSjD and consists of 12 domains. The score varies between 0 (no disease activity) and 123 (max disease activity). The clinESSDAI includes all ESSDAI domains except the biological domain.

    Time frame: Up to 48 weeks

  3. Proportion of responders on STAR (defined as ≥ 5 points) at week 48

    Sjögren's Tool for Assessing Response ( STAR) has been developed as a composite score to assess the efficacy of treatments for PSjD in 5 domains. Patients are classified as STAR responders when they reach ≥ 5 of 9 points.

    Time frame: Up to 48 weeks

  4. Change from baseline in DiSSA joint pain item at week 48

    Diary of Sjögren's Symptoms Assessment (DiSSA) is a patient-reported symptom severity diary that includes 6 PSjD symptoms. Each symptom is rated from 0 (no symptoms) to 10 (worst).

    Time frame: Up to 48 weeks

  5. Change from baseline in DiSSA total score at week 48

    Diary of Sjögren's Symptoms Assessment (DiSSA) is a patient-reported symptom severity diary that includes 6 PSjD symptoms. Each symptom is rated from 0 (no symptoms) to 10 (worst).

    Time frame: Up to 48 weeks

  6. Change from baseline in DiSSA sicca domain at week 48

    Diary of Sjögren's Symptoms Assessment (DiSSA) is a patient-reported symptom severity diary that includes 6 PSjD symptoms. Each symptom is rated from 0 (no symptoms) to 10 (worst).

    Time frame: Up to 48 weeks

  7. Proportion of participants with MCII (minimal clinically important improvement) in ESSDAI (defined as improvement of ≥ 3 points) at week 48

    The ESSDAI was designed to measure systemic disease activity in patients with PSjD and consists of 12 domains. The score varies between 0 (no disease activity) and 123 (max disease activity).

    Time frame: Up to 48 weeks

  8. Change from baseline in clinESSDAI score at week 24

    The ESSDAI was designed to measure systemic disease activity in patients with PSjD and consists of 12 domains. The score varies between 0 (no disease activity) and 123 (max disease activity). The clinESSDAI includes all ESSDAI domains except the biological domain.

    Time frame: Up to 24 weeks

07

Study locations

303 sites

Showing the first 100 of 303 sites across 39 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Jul 2027, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2024
First posted
Nov 12, 2024
StartActual
Jan 15, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2028
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06684847
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Jan 15, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Apr 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)

Start the discussion